UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549


FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  April 4, 2007

GENTA INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)


Delaware

(State or Other Jurisdiction of Incorporation)


0-19635

33-0326866

(Commission File Number)

(IRS Employer Identification No.)

200 Connell Drive
Berkeley Heights, NJ

07922

(Address of Principal Executive Offices)

(Zip Code)


(908) 286-9800

(Registrant’s Telephone Number, Including Area Code)



(Former Name or Former Address, if Changed Since Last Report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)


o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))


o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

 


Item 8.01 Other Events.


On April 4, 2007, Genta Incorporated, (the Company), issued a press release announcing that the Company has filed a formal appeal of the recent non-approvable decision by the Food and Drug Administration (FDA) for the Company’s New Drug Application (NDA) for Genasense® (oblimersen sodium) Injection. The NDA proposed the use of Genasense in combination with chemotherapy for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit
Number

Description

99.1

Press Release of the Company dated April 4, 2007






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

GENTA INCORPORATED

Date: April 4, 2007

By:

/s/ RICHARD J. MORAN

 

 

Name:

Richard J. Moran

 

 

Title:

Senior Vice President,
Chief Financial Officer and Corporate Secretary







EXHIBIT INDEX

Exhibit
Number

Description

Sequentially
Numbered Page

99.1

Press Release of the Company dated April 4, 2007